Boehringer Ingelheim has taken a significant step forward in enhancing its equine health portfolio by acquiring Evax AG, a Swiss biotechnology firm that specializes in equine health solutions.
The Beginnings of Evax AG
Evax AG was founded over a decade ago at the University of Zurich, where it focused on developing therapeutic vaccines aimed at addressing critical unmet needs in equine care. One of the primary areas of focus for Evax has been the treatment of allergic skin diseases in horses, which poses a considerable challenge for veterinarians and horse owners alike.
Innovative Solutions for Allergies
Saskia Kley, the Global Head of Equine at Boehringer Ingelheim, expressed enthusiasm about the potential to provide horse owners with groundbreaking therapeutic options. “This innovative approach targets the underlying causes of allergic skin diseases, potentially leading to longer-lasting effects, improved treatment outcomes, and greater convenience for both horses and their owners,” she stated.
Allergic reactions and skin conditions are prevalent in horses, significantly impacting their overall health and well-being. Current treatment methods often fall short, offering only temporary relief. Traditional therapies, such as shampoos and topical ointments, can be labor-intensive, while others, like corticosteroids, may carry serious safety concerns. Evax’s therapeutic vaccines, which utilize virus-like particles, aim to stimulate the horse’s immune system to produce neutralizing antibodies, directly addressing the root of these health issues.
A Strategic Partnership
Dr. Antonia Gabriel, CEO and Founder of Evax, expressed her excitement about joining forces with Boehringer Ingelheim Animal Health. She emphasized the value of leveraging Boehringer’s expertise in innovation, supply, and commercial strategies as they work to expand therapeutic options for horses.
Boehringer Ingelheim has a long-standing commitment to developing therapeutic vaccines, a focus that has been reinforced through its collaboration with and eventual acquisition of Saiba Animal Health in 2024.
Commitment to Breakthrough Innovation
Knut Elbers, Head of Global Innovation at Boehringer Ingelheim Animal Health, highlighted how the acquisition of Evax aligns with the company’s strategy to spearhead breakthrough innovations in both preventive and therapeutic arenas. He noted that the technology behind virus-like particles represents a pioneering approach in animal healthcare, with the potential to tackle significant unmet medical needs, including chronic illnesses in pets and allergy-related conditions in horses.
A Holistic Approach to Animal Health
Boehringer Ingelheim has established itself as a leader in animal health by providing innovative solutions for preventing and treating diseases in various animal species. The company offers an extensive range of vaccines, parasite control products, and medical treatments tailored for pets, horses, and livestock. Their commitment to improving animal health is rooted in the belief that human and animal health are intricately linked. This perspective drives their mission to positively impact society through advancements in veterinary care.
The Bigger Picture
As a biopharmaceutical entity, Boehringer Ingelheim is dedicated to both human and animal health. With a strong emphasis on research and development, the company strives to create innovative therapies that cater to areas of high unmet medical need. Since its inception in 1885, Boehringer has maintained its independence and a long-term vision for sustainability throughout its operations. With a workforce of approximately 54,300 employees, the company serves over 130 markets, all while aspiring to foster a healthier and more sustainable future.
Conclusion
The acquisition of Evax AG represents a significant advance for Boehringer Ingelheim in the field of equine health, promising innovative solutions for common yet challenging conditions. By integrating Evax’s expertise and technology, Boehringer is poised to enhance the quality of care available for horses, ultimately benefiting both animals and their owners.
- Boehringer Ingelheim has acquired Evax AG, focusing on innovative equine health solutions.
- Evax’s therapeutic vaccines aim to address allergic skin diseases in horses.
- The partnership is expected to enhance treatment options and improve compliance for horse owners.
- Boehringer Ingelheim’s commitment to innovation continues with this acquisition, reinforcing its position in animal health.
- The company emphasizes the interconnectedness of human and animal health in its mission.
Read more → www.finanznachrichten.de
